Nexavar Expansion Plans Suffer Another Blow With Failed Phase III Lung Cancer Trial
This article was originally published in The Pink Sheet Daily
Failed MISSION trial closes a door for Bayer/Onyx’s Nexavar in non-small cell lung cancer. Meanwhile, follow-on regorafenib, also partnered by Bayer and Onyx, is poised for submission in the U.S. and Europe for metastatic colon cancer, with ASCO presentations ahead.
You may also be interested in...
Bayer/Amgen’s Nexavar fails to improve progression-free survival in a Phase III HER2-negative breast cancer study. Approved indications are not affected, the companies note.
Large study tracking drug indications pursued by more than 800 companies over almost a decade finds that only one in 10 wound up getting approved. By therapeutic area, Phase III success rates were lowest in cancer and cardiovascular medicine, and highest in diabetes, infectious and autoimmune disease.
Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.